Dr Helen Rizos

Honorary Principal Research Fellow & Associate Professor
Medicine, Westmead Clinical School
Westmead Millennium Institute for Medical Research

Telephone +61 2 98502762
Fax +61 2 98502701

Map

Selected grants

2014

  • Melanoma resistance to combination BRAF and MEK inhibition is driven by reprogramming of MAPK signaling; Rizos H, Kefford R, Long G; National Health and Medical Research Council (NHMRC)/Project Grants.

2013

  • Melanoma Mutation Profiling For Personalised Treatment; Ziman M, Millward M, Rizos H; National Health and Medical Research Council (NHMRC)/Project Grants.
  • IncuCyte ZOOM; Rizos H, deFazio A, Mann G, Henderson B; DVC Research/Equipment Grant.

2012

  • INCUCYTE LIVE-CELL IMAGING SYSTEM; Rizos H; DVC Research/Cancer Research Fund.
  • The Relationship between B-RAF^V600E and Beta-catenin in Melanoma; Becker T, Rizos H; DVC Research/Bridging Support Grant.
  • Determining the mechanisms of MEK inhibitor resistance in Melanoma; Carlino M, Rizos H; Pfizer Australia Pty Ltd/Research Fellowships.

2011

  • The BD Influx High Speed Cell Sorter; Cunningham A, George J, Rizos H, Clarke C, Reddel R, Kefford R, North K, Stewart G, Jones C, Tam P, Alexander S, Gottlieb D, Bradstock K, Bryan T, Booth D, Bendall L, Brilot-Turville F, Hebbard L, Cooper S, Wang Y, Wang X; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Manipulating oncogenic-signalling pathways in the genesis and treatment of melanoma; Rizos H; Cancer Institute New South Wales/Career Development Fellowship.
  • Melanoma Institute Australia Translational Research Program; Mann G, Thompson J, Kefford R, Menzies S, Scolyer R, Christopherson R, Rizos H, Spillane A, Zhang X, Hersey P; Cancer Institute New South Wales/Translational Program Grant.
  • Characterisation of p14ARF intracellular trafficking pathways; Rizos H; Australian Research Council (ARC)/Discovery Projects (DP).
  • Dissecting PTEN-regulated pathways in the genesis of melanoma; Rizos H; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Manipulating the B-RAF/MEK pathway in the genesis and treatment of melanoma; Rizos H, Kefford R, Long G, Zhang X; National Health and Medical Research Council (NHMRC)/Project Grants.

2010

  • The BD Influx High Speed Cell Sorter; Kefford R, Cunningham A, Bendall L, Clarke C, Harris D, Alexander S, Tam P, Sorrell T, Iredell J, Bryan T, Rizos H, Wang Y, Hebbard L; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2008

  • Molecular determinants of escape from BRAF-induced human melanocyte senescence in the genesis of melanoma; Rizos H; Cancer Institute New South Wales/Early Career Development Fellowship.
  • Escape from BRAF-induced human melanocyte senescence in the genesis of melanoma; Rizos H, Kefford R; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Mitochondrial targeting of the DNA repair protein BARD1; Henderson B, Rizos H; Australian Research Council (ARC)/Discovery Projects (DP).

2007

  • The melanoma-associated ARF tumour suppressor modulates cell proliferation and apoptosis via target protein sumoylation; Rizos H; Cancer Council New South Wales/Research Project Grants.
  • Cameron Melanoma Research Fellowship; Scurr L, Rizos H; Melanoma and Skin Cancer Research Institute/Research Grant.
  • Flow Cytometry support; Alexander S, Braithwaite A, Bradstock K, Bendall L, Gunning P, Henderson B, Kefford R, Reddel R, Rizos H, Jones C, Byrne J; Cancer Institute New South Wales/Infrastructure Grant.

2006

  • Molecular genetics of melanoma predisposition; Mann G, Kefford R, Rizos H, Aitken J, Aitken J; Cancer Council New South Wales/Research Project Grants.

2004

  • The p14ARF tumour suppressor acts as a SUMO E3 ligase; Rizos H; University of Sydney/Cancer Research Fund.
  • Zeiss axiovert 200M cell observer system; Henderson B, Cunningham A, Farrell G, Clarke C, Diefenbach R, Kefford R, Rizos H; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2003

  • Germline mutations identified in melanoma-prone kindreds can impair the function of the p14ARF; Rizos H; National Health and Medical Research Council (NHMRC)/Career Development Fellowship.
  • p14ARF induces p53-independent growth arrest by modulating the activities of the E4F and E2F transcription factors; Rizos H, Kefford R, Huschtscha L; National Health and Medical Research Council (NHMRC)/Project Grants.

2001

  • Germline mutations identified in melanoma-prone kindreds can impair the function of the p14ARF tumour suppressor; Rizos H, Kefford R; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Germline mutations indentified in melanoma-prone kindreds can impair the function of the p14ARF tumour suppressor; Rizos H; National Health and Medical Research Council (NHMRC)/Project Grants.

2000

  • Germline mutations in melanoma-prone kindreds can impair the function of the p14ARF tumour suppressor; Rizos H; Westmead Millenium Institute/Research Support.

1999

  • p16 function in melanocytes; Rizos H; Leo and Jenny Leukaemia and Cancer Foundation/Research Support.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Gowrishankar, K., Carlino, M., Rizos, H. (2013). Acquired Resistance to Targeted MAPK Inhibition in Melanoma. In Guy Huynh Thien Duc (Eds.), Melanoma - From Early Detection to Treatment, (pp. 197-218). Croatia: InTech Open Access Publishers (peer reviewed).
  • Tran, S., Rizos, H. (2013). Monitoring Oncogenic B-RAF-Induced Senescence in Melanocytes. In Lorenzo Galluzzi, Ilio Vitale, Oliver Kepp and Guido Kroemer (Eds.), Methods in Molecular Biology, Cell Senescence: Methods and Protocols, (pp. 313-326). New York: Springer Science + Business Media.
  • Rizos, H., Scurr, L. (2011). Senescence. In Anja Bosserhoff (Eds.), Melanoma Development: Molecular Biology, Genetics and Clinical Application, (pp. 235-254). Vienna: Springer.

Journals

  • Rizos, H., Menzies, A., Pupo, G., Carlino, M., Fung, C., Hyman, J., Haydu, L., Mijatov, B., Becker, T., Boyd, S., Howle, J., Saw, R., Thompson, J., Kefford, R., Scolyer, R., Long, G. (2014). BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clinical Cancer Research, 20(7), 1965-1977. [More Information]
  • Becker, T., Boyd, S., Mijatov, B., Gowrishankar, K., Snoyman, S., Pupo, G., Scolyer, R., Mann, G., Kefford, R., Zhang, X., Rizos, H. (2014). Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor. Oncogene, 33(9), 1158-1166. [More Information]
  • Croft, A., Tay, K., Boyd, S., Guo, S., Jiang, C., Lai, F., Tseng, H., Jin, L., Rizos, H., Hersey, P., et al (2014). Oncogenic Activation of MEK/ERK Primes Melanoma Cells for Adaptation to Endoplasmic Reticulum Stress. The Journal of Investigative Dermatology, 134(2), 488-497. [More Information]
  • Parmenter, T., Kleinschmidt, M., Kinross, K., Bond, S., Li, J., Kaadige, M., Rao, A., Sheppard, K., Hugo, W., Pupo, G., Long, G., Scolyer, R., Rizos, H., et al (2014). Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discovery, 4(4), 423-433. [More Information]
  • Chien, A., Haydu, L., Biechele, T., Kulikauskas, R., Rizos, H., Kefford, R., Scolyer, R., Moon, R., Long, G. (2014). Targeted BRAF Inhibition Impacts Survival in Melanoma Patients with High Levels of Wnt/Beta-Catenin Signaling. PLoS One, 9(4), 1-11. [More Information]
  • Todd, J., Scurr, L., Becker, T., Kefford, R., Rizos, H. (2014). The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma. Oncogene, 33(2), 236-245. [More Information]
  • Carlino, M., Gowrishankar, K., Saunders, C., Pupo, G., Snoyman, S., Zhang, X., Saw, R., Becker, T., Kefford, R., Long, G., Rizos, H. (2013). Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition Following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma. Molecular Cancer Therapeutics, 12(7), 1332-1342. [More Information]
  • Long, G., Wilmott, J., Haydu, L., Tembe, V., Sharma, R., Rizos, H., Thompson, J., Howle, J., Scolyer, R., Kefford, R. (2013). Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment and on progression. Pigment Cell and Melanoma Research, 26(4), 499-508. [More Information]
  • Tran, S., Rizos, H. (2013). Human nevi lack distinguishing senescence traits. Aging, 5(2), 98-99. [More Information]
  • Boyd, S., Mijatov, B., Pupo, G., Tran, S., Gowrishankar, K., Shaw, H., Goding, C., Scolyer, R., Mann, G., Kefford, R., Rizos, H., Becker, T. (2013). Oncogenic B-RAF(V600E) Signaling Induces the T-Box3 Transcriptional Repressor to Repress E-Cadherin and Enhance Melanoma Cell Invasion. The Journal of Investigative Dermatology, 133(5), 1269-1277. [More Information]
  • Fung, C., Pupo, G., Scolyer, R., Kefford, R., Rizos, H. (2013). p16INK4a deficiency promotes DNA hyper-replication and genetic instability in melanocytes. Pigment Cell and Melanoma Research, 26(2), 236-246. [More Information]
  • Ye, Y., Jin, L., Wilmott, J., Hu, W., Yosufi, B., Thorne, R., Liu, T., Rizos, H., Yan, X., Dong, L., Hersey, P., Scolyer, R., et al (2013). PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. Nature Communications, 4(Article number1508), 1-15. [More Information]
  • Todd, J., Becker, T., Kefford, R., Rizos, H. (2013). Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells. Pigment Cell and Melanoma Research, 26(4), 518-526. [More Information]
  • Zhou, L., Pupo, G., Gupta, P., Liu, B., Tran, S., Rahme, R., Wang, B., Rua, R., Rizos, H., Carroll, A., Saksena, N., et al (2012). A parallel genome-wide mRNA and microRNA profiling of the frontal cortex of HIV patients with and without HIV-associated dementia shows the role of axon guidance and downstream pathways in HIV-mediated neurodegeneration. BMC Genomics, 13(November), 1-17. [More Information]
  • Tran, S., Haferkamp, S., Scurr, L., Gowrishankar, K., Becker, T., Desilva, C., Thompson, J., Scolyer, R., Kefford, R., Rizos, H. (2012). Absence of Distinguishing Senescence Traits in Human Melanocytic Nevi. The Journal of Investigative Dermatology, 132(9), 2226-2234. [More Information]
  • Gowrishankar, K., Snoyman, S., Pupo, G., Becker, T., Kefford, R., Rizos, H. (2012). Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition. The Journal of Investigative Dermatology, 132(7), 1850-1859. [More Information]
  • Wilmott, J., Tembe, V., Howle, J., Sharma, R., Thompson, J., Rizos, H., Lo, R., Kefford, R., Scolyer, R., Long, G. (2012). Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine. Molecular Cancer Therapeutics, 11(12), 2704-2708. [More Information]
  • David, M., Huynh, M., Kelly, E., Rizos, H., Coleman, H., Rogers, G., Zoellner, H. (2012). Membrane and cytoplasmic marker exchange between malignant neoplastic cells and fibroblasts via intermittent contact: increased tumour cell diversity independent of genetic change. Journal of Pathology, 228(4), 495-505. [More Information]
  • Scurr, L., McKenzie, H., Becker, T., Irvine, M., Lai, K., Mann, G., Scolyer, R., Kefford, R., Rizos, H. (2012). Selective Loss of Wild-Type p16(INK4a) Expression in Human Nevi. The Journal of Investigative Dermatology, 131(11), 2329-2332. [More Information]
  • Medic, S., Rizos, H., Ziman, M. (2011). Differential PAX3 functions in normal skin melanocytes and melanoma cells. Biochemical and Biophysical Research Communications, 411(4), 832-837. [More Information]
  • Avery-Kiejda, K., Bowden, N., Croft, A., Scurr, L., Kairupan, C., Ashton, K., Talseth-Palmer, B., Rizos, H., Zhang, X., Scott, R., et al (2011). P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC Cancer, 11(203), 1-17. [More Information]
  • Irvine, M., Boyd, S., Frausto, M., Mijatov, B., Gallagher, S., Fung, C., Becker, T., Kefford, R., Rizos, H. (2010). Amino terminal hydrophobic import signals target the p14(ARF) tumor suppressor to the mitochondria. Cell Cycle, 9(4), 829-839. [More Information]
  • Jiang, C., Lai, F., Tay, K., Croft, A., Rizos, H., Becker, T., Yang, F., Liu, H., Thorne, R., Hersey, P., et al (2010). Apoptosis of Human Melanoma Cells Induced by Inhibition of B-RAFV600E Involves Preferential Splicing of BimS. Cell Death and Disease, 1(9), e69-1-e69-14. [More Information]
  • Zhou, L., Diefenbach, E., Crossett, B., Tran, S., Ng, T., Rizos, H., Rua, R., Wang, B., Kapur, A., Gandhi, K., Saksena, N., et al (2010). First evidence of overlaps between HIV-Associated Dementia (HAD) and non-viral neurodegenerative diseases: proteomic analysis of the frontal cortex from HIV+ patients with and without dementia. Molecular Neurodegeneration, 5(27), 27-1-27-20. [More Information]
  • Scurr, L., Pupo, G., Becker, T., Lai, K., Schrama, D., Haferkamp, S., Irvine, M., Scolyer, R., Mann, G., Becker, J., Kefford, R., Rizos, H. (2010). IGFBP7 Is Not Required for B-RAF-Induced Melanocyte Senescence. Cell, 141(4), 717-727. [More Information]
  • Boyd, S., Scurr, L., Fung, C., Haferkamp, S., Kefford, R., Rizos, H. (2010). Oncogenic B-RAF(V600E) Promotes Anchorage-Independent Survival of Human Melanocytes. The Journal of Investigative Dermatology, 130(8), 2144-7. [More Information]
  • McKenzie, H., Fung, C., Becker, T., Irvine, M., Mann, G., Kefford, R., Rizos, H. (2010). Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A. Human Mutation, 31(6), 692-701. [More Information]
  • Haferkamp, S., Scurr, L., Becker, T., Frausto, M., Kefford, R., Rizos, H. (2009). Oncogene-Induced Senescence Does Not Require the p16INK4a or p14ARF Melanoma Tumor Suppressors. The Journal of Investigative Dermatology, 129(8), 1983-1991. [More Information]
  • Becker, T., Haferkamp, S., Dijkstra, M., Scurr, L., Frausto, M., Diefenbach, E., Scolyer, R., Reisman, D., Mann, G., Kefford, R., Rizos, H. (2009). The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a. Molecular Cancer, 8(4), 4-1-4-12. [More Information]
  • Haferkamp, S., Tran, S., Becker, T., Scurr, L., Kefford, R., Rizos, H. (2009). The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence. Aging, 1(6), 542-556. [More Information]
  • McKenzie, H., Scurr, L., Kefford, R., Rizos, H. (2009). Wild type and melanoma-associated mutant p16(IN4a) proteins do not oligomerize in vivo. Pigment Cell and Melanoma Research, 22(1), 131-133. [More Information]
  • Scurr, L., Guminski, A., Chiew, Y., Balleine, R., Sharma, R., Lei, Y., Pryor, K., Wain, G., Brand, A., Byth, K., Kennedy, C., Rizos, H., Harnett, P., deFazio, A. (2008). Ankyrin Repeat Domain 1, ANKRD1, a Novel Determinant of Cisplatin Sensitivity Expressed in Ovarian Cancer. Clinical Cancer Research, 14(21), 6924-6932. [More Information]
  • Haferkamp, S., Becker, T., Scurr, L., Kefford, R., Rizos, H. (2008). p16(INK4a)-induced senescence is disabled by melanoma-associated mutations. Aging Cell, 7(5), 733-745. [More Information]
  • Gallagher, S., Thompson, J., Indsto, J., Scurr, L., Lett, M., Gao, B., Dunleavey, R., Mann, G., Kefford, R., Rizos, H. (2008). p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors. NeoPlasia: an international journal of oncology research, 10(11), 1231-1239. [More Information]
  • Packer, L., Pavey, S., Boyle, G., Stark, M., Ayub, A., Rizos, H., Hayward, N. (2007). Gene expression profiling in melanoma identifies novel downstream effectors of p14ARF. International Journal of Cancer, 121(4), 784-790. [More Information]
  • Rizos, H., Scurr, L., Irvine, M., Alling, N., Kefford, R. (2007). p14ARF Regulates E2F-1 Ubiquitination and Degradation via a p53-Dependent Mechanism. Cell Cycle, 6(14), 1741-1747. [More Information]
  • Rizos, H., McKenzie, H., Ayub, A., Woodruff, S., Becker, T., Scurr, L., Stahl, J., Kefford, R. (2006). Physical and functional interaction of the p14ARF tumor suppressor with ribosomes. Journal of Biological Chemistry, 281(49), 38080-38088. [More Information]
  • Gallagher, S., Kefford, R., Rizos, H. (2006). The ARF tumour suppressor. The International Journal of Biochemistry and Cell Biology, 38(10), 1637-1641. [More Information]
  • Gallagher, S., Kefford, R., Rizos, H. (2005). Enforced expression of p14ARF induces p53-dependent cell cycle arrest but not apoptosis. Cell Cycle, 4(3), 465-472. [More Information]
  • Becker, T., Rizos, H., Dela Pena, A., Leclercq, I., Woodruff, S., Kefford, R., Mann, G. (2005). Impaired inhibition of NF-kappaB activity by melanoma-associated p16INK4a mutations. Biochemical and Biophysical Research Communications, 332(3), 873-879. [More Information]
  • Rizos, H., Woodruff, S., Kefford, R. (2005). p14ARF interacts with the SUMO-conjugating enzyme Ubc9 and promotes the Sumoylation of its binding partners. Cell Cycle, 4(4), 597-603. [More Information]
  • Becker, T., Ayub, A., Kefford, R., Mann, G., Rizos, H. (2005). The melanoma-associated 24 base pair duplication in p16INK4a is functionally impaired. International Journal of Cancer, 117(4), 569-573. [More Information]
  • Rizos, H., Diefenbach, E., Badhwar, P., Woodruff, S., Becker, T., Kefford, R., Rooney, R. (2003). Association of p14ARF with the p120E4F transciptional represssor enhances cell cycle inhibition. Journal of Biological Chemistry, 278(7), 4981-4989.
  • Rizos, H., Diefenbach, E., Badhwar, P., Woodruff, S., Becker, T., Rooney, R., Kefford, R. (2002). Association of p14ARF with the p120E4F Transcriptional Repressor Enhances Cell Cycle Inhibition. Journal of Biological Chemistry, 278(7), 4981-4989.
  • Rizos, H., Puig, S., Badenas,, C., Malvehy, J., Darmanian, A., Jimenez, L., Mila,, M., Kefford, R. (2001). A melanoma-associated germline mutation in exon 1B inactivates p14ARF. Oncogene, 20(39), 5543-5547.
  • Becker, T., Rizos, H., Kefford, R., Mann, G. (2001). Functional Impairment of Melanoma-associated p16 INK4a mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding1. Clinical Cancer Research, 7, 3282-3288.
  • Rizos, H., Darmanian, A., Mann, G., Kefford, R., Holland, E. (2001). Mutations in the INK4a/ARF Melanoma Susceptibility locus functionally impair p14ARF. Journal of Biological Chemistry, 276(44), 41424-41434.
  • Rizos, H., Darmanian, A., Mann, G., Kefford, R. (2000). Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization. Oncogene, 19(26), 2978-2985.

2014

  • Rizos, H., Menzies, A., Pupo, G., Carlino, M., Fung, C., Hyman, J., Haydu, L., Mijatov, B., Becker, T., Boyd, S., Howle, J., Saw, R., Thompson, J., Kefford, R., Scolyer, R., Long, G. (2014). BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clinical Cancer Research, 20(7), 1965-1977. [More Information]
  • Becker, T., Boyd, S., Mijatov, B., Gowrishankar, K., Snoyman, S., Pupo, G., Scolyer, R., Mann, G., Kefford, R., Zhang, X., Rizos, H. (2014). Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor. Oncogene, 33(9), 1158-1166. [More Information]
  • Croft, A., Tay, K., Boyd, S., Guo, S., Jiang, C., Lai, F., Tseng, H., Jin, L., Rizos, H., Hersey, P., et al (2014). Oncogenic Activation of MEK/ERK Primes Melanoma Cells for Adaptation to Endoplasmic Reticulum Stress. The Journal of Investigative Dermatology, 134(2), 488-497. [More Information]
  • Parmenter, T., Kleinschmidt, M., Kinross, K., Bond, S., Li, J., Kaadige, M., Rao, A., Sheppard, K., Hugo, W., Pupo, G., Long, G., Scolyer, R., Rizos, H., et al (2014). Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discovery, 4(4), 423-433. [More Information]
  • Chien, A., Haydu, L., Biechele, T., Kulikauskas, R., Rizos, H., Kefford, R., Scolyer, R., Moon, R., Long, G. (2014). Targeted BRAF Inhibition Impacts Survival in Melanoma Patients with High Levels of Wnt/Beta-Catenin Signaling. PLoS One, 9(4), 1-11. [More Information]
  • Todd, J., Scurr, L., Becker, T., Kefford, R., Rizos, H. (2014). The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma. Oncogene, 33(2), 236-245. [More Information]

2013

  • Gowrishankar, K., Carlino, M., Rizos, H. (2013). Acquired Resistance to Targeted MAPK Inhibition in Melanoma. In Guy Huynh Thien Duc (Eds.), Melanoma - From Early Detection to Treatment, (pp. 197-218). Croatia: InTech Open Access Publishers (peer reviewed).
  • Carlino, M., Gowrishankar, K., Saunders, C., Pupo, G., Snoyman, S., Zhang, X., Saw, R., Becker, T., Kefford, R., Long, G., Rizos, H. (2013). Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition Following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma. Molecular Cancer Therapeutics, 12(7), 1332-1342. [More Information]
  • Long, G., Wilmott, J., Haydu, L., Tembe, V., Sharma, R., Rizos, H., Thompson, J., Howle, J., Scolyer, R., Kefford, R. (2013). Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment and on progression. Pigment Cell and Melanoma Research, 26(4), 499-508. [More Information]
  • Tran, S., Rizos, H. (2013). Human nevi lack distinguishing senescence traits. Aging, 5(2), 98-99. [More Information]
  • Tran, S., Rizos, H. (2013). Monitoring Oncogenic B-RAF-Induced Senescence in Melanocytes. In Lorenzo Galluzzi, Ilio Vitale, Oliver Kepp and Guido Kroemer (Eds.), Methods in Molecular Biology, Cell Senescence: Methods and Protocols, (pp. 313-326). New York: Springer Science + Business Media.
  • Boyd, S., Mijatov, B., Pupo, G., Tran, S., Gowrishankar, K., Shaw, H., Goding, C., Scolyer, R., Mann, G., Kefford, R., Rizos, H., Becker, T. (2013). Oncogenic B-RAF(V600E) Signaling Induces the T-Box3 Transcriptional Repressor to Repress E-Cadherin and Enhance Melanoma Cell Invasion. The Journal of Investigative Dermatology, 133(5), 1269-1277. [More Information]
  • Fung, C., Pupo, G., Scolyer, R., Kefford, R., Rizos, H. (2013). p16INK4a deficiency promotes DNA hyper-replication and genetic instability in melanocytes. Pigment Cell and Melanoma Research, 26(2), 236-246. [More Information]
  • Ye, Y., Jin, L., Wilmott, J., Hu, W., Yosufi, B., Thorne, R., Liu, T., Rizos, H., Yan, X., Dong, L., Hersey, P., Scolyer, R., et al (2013). PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. Nature Communications, 4(Article number1508), 1-15. [More Information]
  • Todd, J., Becker, T., Kefford, R., Rizos, H. (2013). Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells. Pigment Cell and Melanoma Research, 26(4), 518-526. [More Information]

2012

  • Zhou, L., Pupo, G., Gupta, P., Liu, B., Tran, S., Rahme, R., Wang, B., Rua, R., Rizos, H., Carroll, A., Saksena, N., et al (2012). A parallel genome-wide mRNA and microRNA profiling of the frontal cortex of HIV patients with and without HIV-associated dementia shows the role of axon guidance and downstream pathways in HIV-mediated neurodegeneration. BMC Genomics, 13(November), 1-17. [More Information]
  • Tran, S., Haferkamp, S., Scurr, L., Gowrishankar, K., Becker, T., Desilva, C., Thompson, J., Scolyer, R., Kefford, R., Rizos, H. (2012). Absence of Distinguishing Senescence Traits in Human Melanocytic Nevi. The Journal of Investigative Dermatology, 132(9), 2226-2234. [More Information]
  • Gowrishankar, K., Snoyman, S., Pupo, G., Becker, T., Kefford, R., Rizos, H. (2012). Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition. The Journal of Investigative Dermatology, 132(7), 1850-1859. [More Information]
  • Wilmott, J., Tembe, V., Howle, J., Sharma, R., Thompson, J., Rizos, H., Lo, R., Kefford, R., Scolyer, R., Long, G. (2012). Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine. Molecular Cancer Therapeutics, 11(12), 2704-2708. [More Information]
  • David, M., Huynh, M., Kelly, E., Rizos, H., Coleman, H., Rogers, G., Zoellner, H. (2012). Membrane and cytoplasmic marker exchange between malignant neoplastic cells and fibroblasts via intermittent contact: increased tumour cell diversity independent of genetic change. Journal of Pathology, 228(4), 495-505. [More Information]
  • Scurr, L., McKenzie, H., Becker, T., Irvine, M., Lai, K., Mann, G., Scolyer, R., Kefford, R., Rizos, H. (2012). Selective Loss of Wild-Type p16(INK4a) Expression in Human Nevi. The Journal of Investigative Dermatology, 131(11), 2329-2332. [More Information]

2011

  • Medic, S., Rizos, H., Ziman, M. (2011). Differential PAX3 functions in normal skin melanocytes and melanoma cells. Biochemical and Biophysical Research Communications, 411(4), 832-837. [More Information]
  • Avery-Kiejda, K., Bowden, N., Croft, A., Scurr, L., Kairupan, C., Ashton, K., Talseth-Palmer, B., Rizos, H., Zhang, X., Scott, R., et al (2011). P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC Cancer, 11(203), 1-17. [More Information]
  • Rizos, H., Scurr, L. (2011). Senescence. In Anja Bosserhoff (Eds.), Melanoma Development: Molecular Biology, Genetics and Clinical Application, (pp. 235-254). Vienna: Springer.

2010

  • Irvine, M., Boyd, S., Frausto, M., Mijatov, B., Gallagher, S., Fung, C., Becker, T., Kefford, R., Rizos, H. (2010). Amino terminal hydrophobic import signals target the p14(ARF) tumor suppressor to the mitochondria. Cell Cycle, 9(4), 829-839. [More Information]
  • Jiang, C., Lai, F., Tay, K., Croft, A., Rizos, H., Becker, T., Yang, F., Liu, H., Thorne, R., Hersey, P., et al (2010). Apoptosis of Human Melanoma Cells Induced by Inhibition of B-RAFV600E Involves Preferential Splicing of BimS. Cell Death and Disease, 1(9), e69-1-e69-14. [More Information]
  • Zhou, L., Diefenbach, E., Crossett, B., Tran, S., Ng, T., Rizos, H., Rua, R., Wang, B., Kapur, A., Gandhi, K., Saksena, N., et al (2010). First evidence of overlaps between HIV-Associated Dementia (HAD) and non-viral neurodegenerative diseases: proteomic analysis of the frontal cortex from HIV+ patients with and without dementia. Molecular Neurodegeneration, 5(27), 27-1-27-20. [More Information]
  • Scurr, L., Pupo, G., Becker, T., Lai, K., Schrama, D., Haferkamp, S., Irvine, M., Scolyer, R., Mann, G., Becker, J., Kefford, R., Rizos, H. (2010). IGFBP7 Is Not Required for B-RAF-Induced Melanocyte Senescence. Cell, 141(4), 717-727. [More Information]
  • Boyd, S., Scurr, L., Fung, C., Haferkamp, S., Kefford, R., Rizos, H. (2010). Oncogenic B-RAF(V600E) Promotes Anchorage-Independent Survival of Human Melanocytes. The Journal of Investigative Dermatology, 130(8), 2144-7. [More Information]
  • McKenzie, H., Fung, C., Becker, T., Irvine, M., Mann, G., Kefford, R., Rizos, H. (2010). Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A. Human Mutation, 31(6), 692-701. [More Information]

2009

  • Haferkamp, S., Scurr, L., Becker, T., Frausto, M., Kefford, R., Rizos, H. (2009). Oncogene-Induced Senescence Does Not Require the p16INK4a or p14ARF Melanoma Tumor Suppressors. The Journal of Investigative Dermatology, 129(8), 1983-1991. [More Information]
  • Becker, T., Haferkamp, S., Dijkstra, M., Scurr, L., Frausto, M., Diefenbach, E., Scolyer, R., Reisman, D., Mann, G., Kefford, R., Rizos, H. (2009). The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a. Molecular Cancer, 8(4), 4-1-4-12. [More Information]
  • Haferkamp, S., Tran, S., Becker, T., Scurr, L., Kefford, R., Rizos, H. (2009). The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence. Aging, 1(6), 542-556. [More Information]
  • McKenzie, H., Scurr, L., Kefford, R., Rizos, H. (2009). Wild type and melanoma-associated mutant p16(IN4a) proteins do not oligomerize in vivo. Pigment Cell and Melanoma Research, 22(1), 131-133. [More Information]

2008

  • Scurr, L., Guminski, A., Chiew, Y., Balleine, R., Sharma, R., Lei, Y., Pryor, K., Wain, G., Brand, A., Byth, K., Kennedy, C., Rizos, H., Harnett, P., deFazio, A. (2008). Ankyrin Repeat Domain 1, ANKRD1, a Novel Determinant of Cisplatin Sensitivity Expressed in Ovarian Cancer. Clinical Cancer Research, 14(21), 6924-6932. [More Information]
  • Haferkamp, S., Becker, T., Scurr, L., Kefford, R., Rizos, H. (2008). p16(INK4a)-induced senescence is disabled by melanoma-associated mutations. Aging Cell, 7(5), 733-745. [More Information]
  • Gallagher, S., Thompson, J., Indsto, J., Scurr, L., Lett, M., Gao, B., Dunleavey, R., Mann, G., Kefford, R., Rizos, H. (2008). p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors. NeoPlasia: an international journal of oncology research, 10(11), 1231-1239. [More Information]

2007

  • Packer, L., Pavey, S., Boyle, G., Stark, M., Ayub, A., Rizos, H., Hayward, N. (2007). Gene expression profiling in melanoma identifies novel downstream effectors of p14ARF. International Journal of Cancer, 121(4), 784-790. [More Information]
  • Rizos, H., Scurr, L., Irvine, M., Alling, N., Kefford, R. (2007). p14ARF Regulates E2F-1 Ubiquitination and Degradation via a p53-Dependent Mechanism. Cell Cycle, 6(14), 1741-1747. [More Information]

2006

  • Rizos, H., McKenzie, H., Ayub, A., Woodruff, S., Becker, T., Scurr, L., Stahl, J., Kefford, R. (2006). Physical and functional interaction of the p14ARF tumor suppressor with ribosomes. Journal of Biological Chemistry, 281(49), 38080-38088. [More Information]
  • Gallagher, S., Kefford, R., Rizos, H. (2006). The ARF tumour suppressor. The International Journal of Biochemistry and Cell Biology, 38(10), 1637-1641. [More Information]

2005

  • Gallagher, S., Kefford, R., Rizos, H. (2005). Enforced expression of p14ARF induces p53-dependent cell cycle arrest but not apoptosis. Cell Cycle, 4(3), 465-472. [More Information]
  • Becker, T., Rizos, H., Dela Pena, A., Leclercq, I., Woodruff, S., Kefford, R., Mann, G. (2005). Impaired inhibition of NF-kappaB activity by melanoma-associated p16INK4a mutations. Biochemical and Biophysical Research Communications, 332(3), 873-879. [More Information]
  • Rizos, H., Woodruff, S., Kefford, R. (2005). p14ARF interacts with the SUMO-conjugating enzyme Ubc9 and promotes the Sumoylation of its binding partners. Cell Cycle, 4(4), 597-603. [More Information]
  • Becker, T., Ayub, A., Kefford, R., Mann, G., Rizos, H. (2005). The melanoma-associated 24 base pair duplication in p16INK4a is functionally impaired. International Journal of Cancer, 117(4), 569-573. [More Information]

2003

  • Rizos, H., Diefenbach, E., Badhwar, P., Woodruff, S., Becker, T., Kefford, R., Rooney, R. (2003). Association of p14ARF with the p120E4F transciptional represssor enhances cell cycle inhibition. Journal of Biological Chemistry, 278(7), 4981-4989.

2002

  • Rizos, H., Diefenbach, E., Badhwar, P., Woodruff, S., Becker, T., Rooney, R., Kefford, R. (2002). Association of p14ARF with the p120E4F Transcriptional Repressor Enhances Cell Cycle Inhibition. Journal of Biological Chemistry, 278(7), 4981-4989.

2001

  • Rizos, H., Puig, S., Badenas,, C., Malvehy, J., Darmanian, A., Jimenez, L., Mila,, M., Kefford, R. (2001). A melanoma-associated germline mutation in exon 1B inactivates p14ARF. Oncogene, 20(39), 5543-5547.
  • Becker, T., Rizos, H., Kefford, R., Mann, G. (2001). Functional Impairment of Melanoma-associated p16 INK4a mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding1. Clinical Cancer Research, 7, 3282-3288.
  • Rizos, H., Darmanian, A., Mann, G., Kefford, R., Holland, E. (2001). Mutations in the INK4a/ARF Melanoma Susceptibility locus functionally impair p14ARF. Journal of Biological Chemistry, 276(44), 41424-41434.

2000

  • Rizos, H., Darmanian, A., Mann, G., Kefford, R. (2000). Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization. Oncogene, 19(26), 2978-2985.

To update your profile click here. For support on your academic profile contact .